Stockreport

MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains [Seeking Alpha]

MBX Biosciences, Inc.  (MBX) 
PDF MBX's $392M cash balance and recent $200M raise provide funding into 2029, supporting multiple Phase 2/3 readouts and mitigating near-term financial risk. Imapextide [Read more]